L. E. Wagenknecht, C. D. Langefeld, A. L. Scherzinger, J. M. Norris, S. M. Haffner et al., Insulin sensitivity, insulin secretion, and abdominal fat: the Insulin Resistance Atherosclerosis Study (IRAS) Family Study, Diabetes, vol.52, pp.2490-2496, 2003.

E. Ferrannini, B. Balkau, S. W. Coppack, J. M. Dekker, A. Mari et al., Insulin resistance, insulin response, and obesity as indicators of metabolic risk, Journal of Clinical Endocrinology and Metabolism, vol.92, pp.2885-92, 2007.

J. K. Kruit, L. R. Brunham, C. B. Verchere, and M. R. Hayden, HDL and LDL cholesterol significantly influence beta-cell function in type 2 diabetes mellitus, Curr Opin Lipidol, vol.21, pp.178-85, 2010.

C. C. Lee, C. Lorenzo, S. M. Haffner, L. E. Wagenknecht, M. O. Goodarzi et al., Components of metabolic syndrome and 5-year change in insulin clearance-the Insulin Resistance Atherosclerosis Study, Diabetes, obesity & metabolism, vol.15, pp.441-448, 2013.

M. A. Fryirs, P. J. Barter, M. Appavoo, B. E. Tuch, F. Tabet et al., Effects of highdensity lipoproteins on pancreatic beta-cell insulin secretion, Arterioscler Thromb Vasc Biol, vol.30, pp.1642-1650, 2010.

A. Abderrahmani, G. Niederhauser, D. Favre, S. Abdelli, M. Ferdaoussi et al., Human high-density lipoprotein particles prevent activation of the JNK pathway induced by human oxidised low-density lipoprotein particles in pancreatic beta cells, Diabetologia, vol.50, pp.1304-1318, 2007.

B. G. Drew, S. J. Duffy, M. F. Formosa, A. K. Natoli, D. C. Henstridge et al., Highdensity lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus, Circulation, vol.119, pp.2103-2114, 2009.

P. J. Barter, K. A. Rye, J. C. Tardif, D. D. Waters, S. M. Boekholdt et al., Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid A

, Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial, Circulation, vol.124, pp.555-62, 2011.

T. Fall, W. Xie, W. Poon, H. Yaghootkar, R. Magi et al., Using Genetic Variants to Assess the Relationship Between Circulating Lipids and Type 2 Diabetes, Diabetes, vol.64, pp.2676-84, 2015.

J. Jiao, L. Dou, M. Li, Y. Lu, H. B. Guo et al., NADPH oxidase 2 plays a critical role in dysfunction and apoptosis of pancreatic beta-cells induced by very low-density lipoprotein, Mol Cell Biochem, vol.370, pp.103-116, 2012.

E. Lai, U. Pettersson, A. D. Verdugo, P. O. Carlsson, B. Bodin et al., Blood lipids affect rat islet blood flow regulation through beta(3)-adrenoceptors, Am J Physiol Endocrinol Metab, vol.307, pp.653-63, 2014.

M. L. Elks, Chronic perifusion of rat islets with palmitate suppresses glucose-stimulated insulin release, Endocrinology, vol.133, pp.208-222, 1993.

D. T. Stein, V. Esser, B. E. Stevenson, K. E. Lane, J. H. Whiteside et al.,

, Essentiality of circulating fatty acids for glucose-stimulated insulin secretion in the fasted rat, J Clin Invest, vol.97, pp.2728-2763, 1996.

Y. Sako and V. E. Grill, A 48-hour lipid infusion in the rat time-dependently inhibits glucoseinduced insulin secretion and B cell oxidation through a process likely coupled to fatty acid oxidation, Endocrinology, vol.127, pp.1580-1589, 1990.

T. M. Mason, T. Goh, V. Tchipashvili, H. Sandhu, N. Gupta et al., Prolonged elevation of plasma free fatty acids desensitizes the insulin secretory response to glucose in vivo in rats, Diabetes, vol.48, pp.524-554, 1999.

E. Rebelos, M. Seghieri, A. Natali, B. Balkau, A. Golay et al., Influence of endogenous NEFA on beta cell function in humans, Diabetologia, vol.58, pp.2344-52, 2015.

A. C-c-e-p-t-e-d-m-a-n-u-s-c-r-i-p-t-accepted and . Manuscript,

A. Carpentier, S. D. Mittelman, R. N. Bergman, A. Giacca, and G. F. Lewis, Prolonged elevation of plasma free fatty acids impairs pancreatic beta-cell function in obese nondiabetic humans but not in individuals with type 2 diabetes, Diabetes, vol.49, pp.399-408, 2000.

S. Kashyap, R. Belfort, A. Gastaldelli, T. Pratipanawatr, R. Berria et al.,

, A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes, Diabetes, vol.52, pp.2461-74, 2003.

M. Manco, A. Bertuzzi, S. Salinari, A. Scarfone, M. Calvani et al., The ingestion of saturated fatty acid triacylglycerols acutely affects insulin secretion and insulin sensitivity in human subjects, The British journal of nutrition, vol.92, pp.895-903, 2004.

O. Pivovarova, W. Bernigau, T. Bobbert, F. Isken, M. Mohlig et al., Hepatic insulin clearance is closely related to metabolic syndrome components, Diabetes Care, vol.36, pp.3779-85, 2013.

A. Kotronen, S. Vehkavaara, A. Seppala-lindroos, R. Bergholm, and H. Yki-jarvinen, Effect of liver fat on insulin clearance, American journal of physiology Endocrinology and metabolism, vol.293, pp.1709-1724, 2007.

M. Hao, W. S. Head, S. C. Gunawardana, A. H. Hasty, and D. W. Piston, Direct effect of cholesterol on insulin secretion: a novel mechanism for pancreatic beta-cell dysfunction, Diabetes, vol.56, pp.2328-2366, 2007.

N. Sattar, D. Preiss, H. M. Murray, P. Welsh, B. M. Buckley et al., Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials, Lancet, vol.375, pp.735-777, 2010.

H. Cederberg, A. Stancakova, N. Yaluri, S. Modi, J. Kuusisto et al., Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort, Diabetologia, vol.58, pp.1109-1126, 2015.

A. C-c-e-p-t-e-d-m-a-n-u-s-c-r-i-p-t-accepted and . Manuscript,

S. A. Hills, B. Balkau, S. W. Coppack, J. M. Dekker, A. Mari et al., The EGIR-RISC Study (the European group for the study of insulin resistance: Relationship between insulin sensitivity and cardiovascular disease risk): I. Methodology and Objectives, Diabetologia, vol.47, pp.566-70, 2004.

A. Mari, O. Schmitz, A. Gastaldelli, T. Oestergaard, B. Nyholm et al., Meal and oral glucose tests for the assessment of ß-cell function: modeling analysis in normal subjects

, Am J Physiol Endocrinol Metab, vol.283, pp.1159-66, 2002.

E. Van-cauter, F. Mestrez, J. Sturis, and K. S. Polonsky, Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for Cpeptide clearance, Diabetes, vol.41, pp.368-77, 1992.

L. R. Brunham, J. K. Kruit, T. D. Pape, J. M. Timmins, A. Q. Reuwer et al., Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment, Nature medicine, vol.13, pp.340-347, 2007.

J. K. Kruit, P. H. Kremer, L. Dai, R. Tang, P. Ruddle et al., Cholesterol efflux via ATP-binding cassette transporter A1 (ABCA1) and cholesterol uptake via the LDL receptor influences cholesterol-induced impairment of beta cell function in mice

, Diabetologia, vol.53, pp.1110-1119, 2010.

J. Besseling, J. J. Kastelein, J. C. Defesche, B. A. Hutten, and G. K. Hovingh, Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus, JAMA, vol.313, pp.1029-1065, 2015.

A. Sharif, V. Ravindran, R. Moore, G. Dunseath, S. Luzio et al., The effect of rosuvastatin on insulin sensitivity and pancreatic beta-cell function in nondiabetic renal transplant recipients, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, vol.9, p.1439, 2009.

A. C-c-e-p-t-e-d-m-a-n-u-s-c-r-i-p-t-accepted and . Manuscript,

J. A. Paniagua, J. Lopez-miranda, A. Escribano, F. J. Berral, C. Marin et al.,

, Cerivastatin improves insulin sensitivity and insulin secretion in early-state obese type 2 diabetes, Diabetes, vol.51, pp.2596-603, 2002.

N. Yaluri, S. Modi, L. Rodriguez, M. Stancakova, A. Kuusisto et al.,

, Simvastatin Impairs Insulin Secretion by Multiple Mechanisms in MIN6 Cells, PLoS One, vol.10, p.142902, 2015.

A. Mari, A. Gastaldelli, A. Natali, T. Ostergard, O. Schmitz et al., Characterization of ?-cell function impairment in first-degree relatives of type 2 diabetic subjects: Modeling analysis of 24-h triple-meal tests, American Journal of Physiology-Endocrinology and Metabolism, vol.288, 2005.

A. L. Siebel, A. K. Natoli, F. Y. Yap, A. L. Carey, M. Reddy-luthmoodoo et al., Effects of high-density lipoprotein elevation with cholesteryl ester transfer protein inhibition on insulin secretion, Circ Res, vol.113, pp.167-75, 2013.

M. R. Rickels, E. S. Goeser, C. Fuller, C. Lord, A. M. Bowler et al., Loss-offunction mutations in ABCA1 and enhanced beta-cell secretory capacity in young adults, Diabetes, vol.64, pp.193-202, 2015.

C. P. Briscoe, M. Tadayyon, J. L. Andrews, W. G. Benson, J. K. Chambers et al., The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids, J Biol Chem, vol.278, pp.11303-11314, 2003.

M. Fizelova, M. Miilunpohja, A. J. Kangas, P. Soininen, J. Kuusisto et al., Associations of multiple lipoprotein and apolipoprotein measures with worsening of glycemia and incident type 2 diabetes in 6607 non-diabetic Finnish men, Atherosclerosis, vol.240, pp.272-279, 2015.

A. C-c-e-p-t-e-d-m-a-n-u-s-c-r-i-p-t-accepted and . Manuscript,

A. Tenenbaum, M. Motro, E. Z. Fisman, E. Schwammenthal, Y. Adler et al.,

, Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease, Circulation, vol.109, pp.2197-202, 2004.

H. Tenenbaum, S. Behar, V. Boyko, Y. Adler, E. Z. Fisman et al., Long-term effect of bezafibrate on pancreatic beta-cell function and insulin resistance in patients with diabetes, Atherosclerosis, vol.194, pp.265-71, 2007.

Z. F. Kang, Y. Deng, Y. Zhou, R. R. Fan, J. C. Chan et al., Pharmacological reduction of NEFA restores the efficacy of incretin-based therapies through GLP-1 receptor signalling in the beta cell in mouse models of diabetes, Diabetologia, vol.56, pp.423-456, 2013.

M. Adiels, S. O. Olofsson, M. R. Taskinen, and J. Boren, Diabetic dyslipidaemia. Current opinion in lipidology, vol.17, pp.238-284, 2006.